Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GB:GSK) ) just unveiled an update.
GSK has secured approval from China’s National Medical Products Administration for its multiple myeloma drug Blenrep (belantamab mafodotin), in combination with bortezomib and dexamethasone, for adults with relapsed or refractory disease after at least one prior therapy. The decision, granted after priority review and Breakthrough Therapy Designation, makes Blenrep the only anti-BCMA option approved from the second line in China and the only fully outpatient anti-BCMA therapy.
The green light is based on phase III DREAMM-7 data, in which the Blenrep combo cut the risk of death by 42% and nearly tripled median progression-free survival compared with a daratumumab-based regimen, while maintaining a manageable safety profile. With multiple myeloma cases and mortality rising sharply in China, the approval strengthens GSK’s position in the competitive oncology market and adds a differentiated, easily administered treatment option that can be delivered in community settings, potentially easing pressure on hospitals and broadening patient access.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £22.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on developing medicines and vaccines across oncology and other therapeutic areas, aiming to unite science, technology and talent to get ahead of disease. In cancer, the group is expanding from blood and women’s cancers into lung, gastrointestinal and other solid tumours, with a particular emphasis on antibody-drug conjugates and targeted therapies.
Average Trading Volume: 9,512,590
Technical Sentiment Signal: Buy
Current Market Cap: £85.13B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.